European drugmakers are urging the EU to allow higher medicine prices, warning that without stronger investment incentives, ...

In what could be seen as a bellwether for the pharmaceutical industry's sweeping shift toward localised manufacturing—spurred ...

The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European ...

Granite will focus on two antibody therapies, both targeting crucial players in the inflammatory cascade to address ...

Granite Bio is ready to rock 'n' roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting ...

Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it ...

Pharmaceutical companies in Europe are requesting the EU to adopt drug pricing strategies comparable to the US.

Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

CEOs from European drugmakers Sanofi and Novartis have inked a letter in The Financial Times urging the European Union to set ...

Novartis is set to invest $23 billion in US-based manufacturing and research and development (R&D) over the next five years, ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

A Swiss drug giant has gotten the message from President Trump’s tariff threats. Novartis said Thursday it will spend $23 ...